1. **PURPOSE**
   The purpose of this standard operating procedure (SOP) is to describe the processes for establishing and maintaining written SOP’s. The purpose of having written SOPs is to: promote quality and consistency in the ethics review process; ensure compliance with the principles, guidelines and regulations applicable to the ethics review and oversight of research involving humans; and facilitate training of new personnel.

2. **GENERAL POLICY STATEMENT**
   Written SOPs provide the framework to promote ethical standards in the review, oversight and conduct of research involving human participants. SOPs describe the processes that must be followed and documented to assure that the rights and welfare of the human participants of such research are overseen and protected in a uniform manner.

3. **RESPONSIBILITY**
   This SOP applies to all HSREB members including the HSREB Chair, Vice-Chairs and to all Office of Human Research Ethics (OHRE) personnel.

   The Director of Research Ethics is responsible for coordinating the review and modification of the SOPs.

   The Director of Research Ethics and HSREB Chair and/or Vice-Chair is responsible for granting final SOP approval.

4. **DEFINITIONS**
   See glossary of terms

5. **SPECIFIC POLICIES AND PROCEDURES.**
5.1 **Development, Review, Revision and Approval of Policies and Procedures**
5.1.1 The Director of Research Ethics or designee will review the SOPs at least biennially. Applicable SOPs will be reviewed sooner if changes to regulations, guidelines, or standard practice warrant revisions or the creation of new SOPs.

5.1.2 SOPs may be revised for reasons including but not limited to: changes to regulations or guidelines, new policies, or changes to REB or administrative practices;
5.1.3 The Director of Research Ethics, the research Ethics Officer (EO) or qualified HSREB office personnel will make the necessary modifications to existing SOPs, or draft a new SOP(s). SOPs are controlled documents and new drafts will be indicated by the addition of “DRAFT version date” and removal of the previous “Final Version Date”;

5.1.4 The revised SOP(s) will be circulated to the OHRE personnel and HSREB Chair and/or Vice-Chair(s), as well as HSREB members (as appropriate) for review. Comments will be incorporated into a new version with an updated version date;

5.1.5 Once the SOP content is approved, the draft version date will be removed and the date of the approved version will be entered as the “Final Version Date”. The history of revisions will be recorded in the tracked copies of each SOP;

5.1.6 Signatures of the Director of Research Ethics and the HSREB Chair and/or Vice Chair will demote SOP approval. A new final version of the SOP supersedes any previous versions;

5.1.7 SOPs will be archived for 25 years (per Health Canada requirements).

5.2 Distribution and Communication

5.2.1 New or revised SOPs and associated guidance documents will be communicated and disseminated to all individuals identified in the “Responsibilities” section of each SOP;

5.2.2 The SOPs will be available to the investigator sites served by the HSREB;

5.2.3 The EO or designee will train all members of the HSREB and the OHRE office on any new or revised policy and/or relevant procedures, as applicable;

5.2.4 Each new HSREB member must review all applicable policies and procedures prior to undertaking his/her responsibilities as an HSREB member;

5.2.5 Each new OHRE staff member must review all applicable policies and procedures prior to undertaking his/her responsibilities with the OHRE;

5.2.6 The OHRE shall maintain all documentation of SOP training.

5.3 Forms, Memos and Guidance Documents

5.3.1 Forms such as checklists and worksheets may be developed to facilitate compliance with the SOPs and to ensure that policies are integrated into daily operations. Forms may be either controlled or non-controlled;

5.3.2 Memos and guidance documents may be developed to provide guidance for the interpretation and implementation of the SOP;

5.3.3 Memos and guidance documents will be made available to the investigator sites;

5.3.4 The Director of Research Ethics or designee will evaluate the need for new or revised forms, memos or guidance documents.

6. REFERENCES


6.2. International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines;

6.3. Health Canada Therapeutic Products Directorate Food and Drug Regulations for Clinical Trials, Division 5

6.5. US Department of Health and Human Services (HHS) CFR Title 45 Parts 46.103, 46.108, 46.115.

7. **SOP HISTORY**

<table>
<thead>
<tr>
<th>SOP Number-Version</th>
<th>Key Changes</th>
<th>Effective Date mm/dd/yyyy</th>
</tr>
</thead>
<tbody>
<tr>
<td>101.001</td>
<td>Original</td>
<td>06/14/2013</td>
</tr>
<tr>
<td>101.002</td>
<td>Template was updated</td>
<td>06/20/2014</td>
</tr>
<tr>
<td>101.003</td>
<td>Minor Administrative changes</td>
<td>05/22/2014</td>
</tr>
<tr>
<td>101.004</td>
<td>Minor Administrative changes</td>
<td>05/10/2016</td>
</tr>
<tr>
<td>101.005</td>
<td>Minor Administrative Changes</td>
<td>09/06/2018</td>
</tr>
<tr>
<td>101.006</td>
<td>Minor Administrative Changes</td>
<td>13/02/2020</td>
</tr>
</tbody>
</table>